Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
The Paradigm of Technological Innovations from Open to Scarless Surgery for Colorectal Cancer
1
4
42097
10.30476/mejc.2018.42097
EN
Salman Yousuf
Guraya
Clinical Sciences Department, College of Medicine, University of Sharjah, UAE
Journal Article
2017
12
30
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Red Meat Consumption and Breast Cancer Risk in Premenopausal Women: A Systematic Review and Meta-Analysis
5
12
42096
10.30476/mejc.2018.42096
EN
Abbas
Rezaianzadeh
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-0067-0659
Mohammad
Ghorbani
The Collaboration Center of Meta-Analysis Research, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
Shahab
Rezaeian
Research Center for Environmental Determinants of Health (RCEDH), Kermanshah University of Medical Sciences, Kermanshah, Iran
0000-0002-3997-5687
Aziz
Kassani
Department of Community Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
Journal Article
2017
04
15
Background: This comprehensive meta-analysis aimed to determine the impact of red meat consumption on breast cancer risk in premenopausal women.Methods: We conducted a systematic search in major electronic databases (MEDLINE, Scopus, and ScienceDirect) until January 1st, 2016 for all the casecontrol and cohort studies that addressed the association between red meat consumption and breast cancer risk. The full-texts of the retrieved articles were reviewed by two independent authors. The quality of the studies was assessed using a score assigned to each item according to STROBE statement. We used the random effects model to obtain summary measures of odds ratio or relative risk with 95% confidence interval.Results: Out of the 513 retrieved studies, 17 (9 case-control and 8 cohort) were entered into the meta-analysis. These studies analyzed 26675 cases of breast cancer and over 943557 control or comparison subjects. The results of the random effects metaanalysis indicated a significant association between red meat consumption and breast cancer risk (relative risk: 1.269; 95% confidence interval: 1.117, 1.441; P-value for heterogeneity=0.002). The pooled relative risk was 1.087 (95% confidence interval: 0.999, 1.183) for cohort studies and 1.548 (95% confidence interval: 1.255, 1.909) for case-control studies.Conclusion: The results of this meta-analysis showed that the women who consumed red meat had an increased risk of breast cancer. Further studies are required to investigate this association.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Investigation of Programmed Cell Death-1 (PD-1) Gene Variations at Positions PD1.3 and PD1.5 in Iranian Patients with Non-small Cell Lung Cancer
13
17
42095
10.30476/mejc.2018.42095
EN
Zahra
Piredelkhosh
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Tohid
Kazemi
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
0000-0002-8583-1270
Mohammad Reza
Haghshenas
Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Mohammad Ali
Ghayumi
Department of Internal Medicine, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Nasrollah
Erfani
Department of Internal Medicine, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-4158-9128
Journal Article
2017
12
30
Background: Tumor cells express PD-1 ligands to bind PD-1 on immune cells and escape immune responses. In the present study, we aimed to investigate whether single nucleotide polymorphisms at positions PD1.3 (+7146, rs11568821) G/A, and PD1.5 (+7785 C/T, rs2227981) may be considered risk factors for susceptibility to nonsmall cell lung cancer in the Iranian population. Methods: This study enrolled 206 histopathologically confirmed lung cancer patients and 173 age/sex matched healthy controls. We performed PCR-RFLP to determine the genotypes of the extracted genomic DNA.Results: The frequencies of PD1.3 GG, GA and AA genotypes were 171 (83%), 31 (15%) and 4 (1.9%) out of 206 patients, and 144 (83.2%), 26 (15%), and 3 (1.7%) out of 173 controls, respectively. The frequencies of PD1.5 CC, CT and TT genotypes were 78 (37.9%), 100 (48.5%), and 28 (13.6%) in patients, and 60 (34.7%), 89 (51.4%), and 24 (13.9%) in controls. There were no significant differences in genotype analysis between patients and controls at positions PD1.3 (P=0.98) or PD1.5 (P=0.80). No significant differences existed in the frequencies of alleles and haplotypes between the two groups (P>0.05).Conclusion: Our data have indicated no association between PD1.3 (+7146) G/A and PD1.5 (+7785) C/T with susceptibility to non-small cell lung cancer. Investigation of other PD1 genetic variations and emerged haplotypes are required to completely define the role of PD1 genetic variations in susceptibility to lung cancer.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Prognostic Impact of Adjuvant Radiotherapy in Breast Cancer Patients with One to Three Positive Axillary Lymph Nodes
19
25
42099
10.30476/mejc.2018.42099
EN
Mansour
Ansari
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-8249-1776
Behnam
Kadkhodaei
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
Mehdi
Shariat
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-7540-9172
Abdolrasoul
Talei
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0001-9111-3681
Majid
Akrami
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0001-6627-2648
Vahid
Zangouri
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-6749-6755
Niloofar
Ahmadloo
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0003-3178-8577
Mohammad
Mohammadianpanah
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0001-9391-8977
Sayed Hasan
Hamedi
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-2050-5909
Hamid
Nasrolahi
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
Shapour
Omidvari
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0003-3656-9891
Ahmad
Mosalaei
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-3986-8865
Journal Article
2017
03
02
Background: Radiotherapy, as an adjuvant treatment, plays a well-known role in prevention of locoregional recurrence in breast cancer patients. This study aims to investigate the impact of radiotherapy in patients with N1 disease.Methods: In this retrospective study, we reviewed the characteristics and treatment outcomes of 316 patients with a biopsy proven diagnosis of breast carcinoma and 1-3 positive axillary lymph nodes. The patients received treatment between 1995 and 2014. The patients had a median follow-up of 60 (range: 6-182) months.Results: This study was conducted on 316 patients with a median age of 48 (range: 26-86) years. Among patients, 215 underwent modified radical mastectomy and 101 had breast-conserving surgery before adjuvant treatment. Indeed, 259 patients received radiotherapy (radiation group) and 57 did not (control group). There was locoregional recurrence in one control group patient and two patients in the radiation group. Multivariate analysis results indicated hormone receptor status as an independent prognostic factor for the 5-year disease-free survival rate. Estrogen and progesterone receptor negativity (HR = 1.80, 95% CI: 1.02-3.19, P=0.043) also had a negative influence on the 5-year disease-free survival rate. However, radiotherapy had no significant effect on disease-free survival (P=0.446) and overall survival (P=0.058) rates.Conclusion: The results showed that adjuvant radiotherapy had no prognostic impacts on locoregional and distant disease control in breast cancer patients with N1 disease.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Clinicopathologic Features and Survival of Breast Cancer Subtypes in Northeast Iran
27
33
42101
10.30476/mejc.2018.42101
EN
Soodabeh
Shahidsales
Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Mona
Joudi
Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Marjaneh
Mirsadraee
Reza Radiotherapy Oncology Center, Mashhad, Iran
Amir
Avan
Molecular Medicine Group, Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
0000-0002-4968-0962
Saeideh
Ahmadi Simab
Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Mohammad-Reza
Ghavamnasiri
Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Journal Article
2017
04
19
Background: Breast cancer can be categorized into different histopathological subtypes based on gene expression profiles. The aim of this study was to evaluate the clinicopathological features and overall survival (OS) of various subtypes of breast cancer in order to help diagnosis and guide treatment. Method: The clinicopathologic features of 1095 patients with breast cancer diagnosed over a 10–year period between 2001 and 2011were analyzed. Kaplan–Meier method was used to analyze the disease-free survival (DFS) and overall survival (OS). Calculation of hazard ratio (HR) was conducted by multivariate Cox regression.Results: According to the clinicopathologic characteristics of 1095 cases, 42% were luminal A subtype, 19.2% luminal B, 23% triple negative and 15% Her-2+. The lowest (46.88±12.59 years) and highest (50.54±12.32 years) mean age were in triple negative and Her2+ groups, respectively. There was a significant correlation between histology subtype and age, BMI, lymph node, type of surgery, and stage of disease. Overall survival (OS) and disease free survival (DFS) were significantly shorter in Her-2+ breast cancer patients (P< 0.001). Multivariate analysis showed that age had the highest hazard ratio of 2.481(CI 1.375- 4.477).Conclusion: The results of this study showed the importance of clinicopathological studies of molecular types which helps early diagnosis and identification of best strategy to treat the disease.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Evaluation of an Immunomodulator Drug as a Radioprotectant on Human Peripheral Blood Lymphocytes In Vitro
35
40
42102
10.30476/mejc.2018.42102
EN
Zahra
Sattarpour
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Bahzad
Baradaran
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
0000-0002-8642-6795
Alireza
Farajollahi
Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Mohammad
Asghari Jafarabadi
Department of Statistics and Epidemiology, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
Vahid
Khazeh
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Jalil
Pirayesh Islamian
Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Journal Article
2017
05
03
Background: IMOD™, a selenium enriched extract of the plants Tanacetum vulgare, Urtica dioica, and Rosa canina, has an excellent effect on oxidative stress. In this study, we investigated the radioprotective effects of this immunomodulatory drug on human peripheral blood lymphocytes.Methods: Peripheral blood samples obtained from venipuncture of the brachial vein were treated with IMOD™ (5, 10, 15, 20 μl) for 30 min and Cobalt 60 γ-rays (0.25, 0.5, 1, 2 Gy) as the test groups and cultured with the control. We used the micronuclei assay, cell death detection, and cell toxicity assay to analyze the treatment effects.Results: The frequency of micronuclei were 1.66 (0 Gy), 5.33 (0.25 Gy), 9.67 (0.5 Gy), 17.67 (1 Gy), and 23.67 (2 Gy) in the irradiated lymphocytes (P<0.001). The percentage of micronuclei frequency reduced to 20%, 26.83%, 37.68%, 16%, and 20.47% with IMOD™. Apoptosis and necrosis decreased significantly in the IMOD™ treated groups (P<0.05).Conclusion: IMOD™ may protect these cells against ionizing radiation.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy
41
47
42103
10.30476/mejc.2018.42103
EN
Aziz
Rezapour
Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
Javad
Javan-Noughabi
Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
Ahmad
Faramarzi
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Touraj
Harati Khalilabad
Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
Sajjad
Vahedi
Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
Abedin
Teymourizad
Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
Journal Article
2016
12
07
Background: Quality of life has become a part of the evaluation criteria for cancer therapy. The aim of this study was to evaluate the quality of life in breast cancer patients under chemotherapy regimens that contained doxorubicin and cyclophosphamide (AC) compared to paclitaxel and gemcitabine (PG).Methods: This cohort study evaluated 100 women with breast cancer treated by doxorubicin and cyclophosphamide or gemcitabine and paclitaxel regimens. We used the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 to assess health related quality of life at the beginning and end of chemotherapy. Data were analyzed by the independent t-test at a significance level of 0.05.Results: Most of the 100 patients were married (68%), aged 41-50 years (36%), non-college educated (76%), and had insurance (97%). The mean quality of life scores at the first session of chemotherapy and prior to the onset of treatment-related adverse events were 71.33 for the doxorubicin and cyclophosphamide groups and 71.15 for the gemcitabine and paclitaxel groups. Analysis of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 at the last chemotherapy session showed that the quality of life in both groups deteriorated as a result of side effects. The mean of quality of life scores at the first session of chemotherapy were 66.49 for the doxorubicin and cyclophosphamide group and 59.99 for the gemcitabine and paclitaxel group.Conclusion: Strategies to improve the emotional and role functions of the patients who undergo treatment should be given priority. Financial difficulties faced by breast cancer patients should be addressed from a policy making level at the initiating health financing system.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Clustering of Breast Cancer Cases among Women from Kurdistan Province, Iran: A Population-based Cross-sectional Study
49
55
42104
10.30476/mejc.2018.42104
EN
Seyed Mehdi
Hosseini
Student Research Committee, Department of Epidemiology, Hamadan University of Medical Sciences, Hamadan, Iran
Masoud
Parvin
Student Research Committee, Department of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran
Payam
Shokri
Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
Milad
Fadaie
Department of Biotechnology, Hamadan University of Medical Sciences, Hamadan, Iran
Bahman
Ghaytasi
Department of Public Health and Disease Prevention and Control Center, Health Deputy, Kurdistan University of Medical Sciences, Sanandaj, Iran
Manoochehr
Khondabi
Student Research Committee, Department of Epidemiology, Hamadan University of Medical Sciences, Hamadan, Iran
Meysam
Olfatifar
Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
Student Research Committee, Department of Epidemiology, Hamadan University of Medical Sciences, Hamadan, Iran
Ebrahim
Chavoshi
Faculty of Agriculture, Bu Ali Sina University, Hamadan, Iran
Journal Article
2017
01
30
Background: Spatial analysis is one of the required tools of epidemiology and public health sciences. This study intends to detect significant clusters of breast cancer cases in Kurdistan Province, Iran.Methods: We obtained data that pertained to breast cancer cases during 2005-2014 from the Health Deputy at Kurdistan University of Medical Sciences. After application of spatial scan statistics to detect the purely spatial (aggregation of cases in particular locations of space) and space-time (diseases clusters in space that depend on the time period) clusters, we calculated the population attribution risk (%) values to better distinguish the detected clusters.Results: We observed that the second secondary purely spatial cluster (P=0.0051) had the highest population attribution risk (%) of 3.8 and the primary space-time unadjusted cluster (P=0.0019) had the lowest population attribution risk (%) of 0.67 of all the detected clusters. Before we applied the adjustment, both the space-time and purely spatial clusters had similar locations. However, after adjustment for age, the space-time clusters location shifted and population attribution risk (%) values changed (between 0.02 and 0.4).Conclusion: Population attribution risk (%) value differences and clusters’ temporal and spatial variations before and after adjustments can represent disease interventions impact. Additional studies should be conducted to strengthen the registering and reporting system to determine other influencing factors.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Trends in Cervical Cancer Incidence in Iran from 2003 to 2009
57
63
42093
10.30476/mejc.2018.42093
EN
Shahla
Chaichian
Minimally Invasive Techniques Research Center in Women, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
Sorour
Khateri
Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
Yousef
Moradi
Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Science, Tehran, Iran
Fatemeh
Khosravi Shadmani
Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Kamyar
Mansori
Social Development and Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran
School of Nursing and Midwifery, Islamic Azad University-Sannandaj Branch, Sanandaj, Iran
0000-0003-3527-4741
Zaher
Khazaei
Dezful University of Medical Sciences, Dezful, Iran
Farhad
Moradpour
Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
Fatemeh
Varse
Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
Journal Article
2017
01
31
Background: Cancer is the second leading cause of death worldwide and the third in Iran. Among cancers, cervical cancer is the third leading cause of death in women. Thus, recognizing the epidemiology and trends of cervical cancer can be effective for planning and policy-making. This study aims to investigate the incidence and trends of cervical cancer in Iran due to the few studies that have addressed this issue and the unclear trend for cervical cancer in Iran.Methods: This study re-analyzed existing data from the cancer data recording system in Iran during years 2003 to 2009. We used available data from the National Cancer Registry and Center for Disease Control of the Ministry of Health, Treatment and Medical Education. Stata software (version 11) was used for data analysis and the significance of the incidence trend diagram was derived with WINPEPI software.Results: Assessment of the National Cancer Registry statistics from 2003 to 2009 showed an increased trend in cervical cancer from 2003 to 2008 and a decreased trend from 2008 to 2009. During this period, there were 4273 cases of cervical cancer registered. From these, 394 cases were registered in 2003 which peaked at 907 cases in 2009. The registered cancer cases had an approximately 3-fold increase during this period. Most provinces reported an increased trend of incidence in cervical cancer.Conclusion: Based on the results of this study, the incidence of cervical cancer is increasing in Iran, especially in the central regions of the country. Therefore, considering the growing trend of cancer, we recommend early detection through screening programs, public awareness, and public training programs that particularly target high risk populations.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Solitary Fibrous Tumor of the Parotid Gland in a Young Female: A Rare Case Report and Review of the Literature
65
69
42094
10.30476/mejc.2018.42094
EN
Megha
Ralli
Department of Pathology, Pt. B.D. Sharma PGIMS Rohtak, Haryana, India
Nisha
Marwah
Department of Pathology, Pt. B.D. Sharma PGIMS Rohtak, Haryana, India
Mansi
Agarwal
Department of Pathology, Pt. B.D. Sharma PGIMS Rohtak, Haryana, India
Anshul
Sawhney
Department of Dentistry, UPUMS, Saifai, Etawah, India
Yashika
Bhatia
Department of Pathology, Pt. B.D. Sharma PGIMS Rohtak, Haryana, India
Nitesh
Kumari
Department of Pathology, Pt. B.D. Sharma PGIMS Rohtak, Haryana, India
Journal Article
2017
01
04
Solitary fibrous tumor is a rare tumor of the salivary gland. To date, 27 cases have been reported. The clinical and radiological features are the same as other lesions of the parotid gland. Hence, light microscopy and immunostaining is important to confirm the diagnosis. Fine needle aspiration cytology yield depends on the area sampled and can be inconclusive in many cases. Treatment of choice is complete surgical excision with regular long-term follow up. Most cases are benign, however three malignant cases have been reported. Here, we report a case of solitary fibrous tumor in the parotid gland seen in a 14-year old female diagnosed by histopathological examination and immunohistochemistry analysis.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Vulvar Villoglandular Adenocarcinoma of Colonic Type: A Rare Finding
71
75
42100
10.30476/mejc.2018.42100
EN
Heidarali
Esmaeili
Department of General Pathology, Tabriz University of Medical Sciences, Tabriz, Iran
Mahzad
Azimpouran
Department of General Pathology, Tabriz University of Medical Sciences, Tabriz, Iran
Elaheh
Olad-Saheb-Madarek
Department of Obstetrics and Gynecology, Tabriz University of Medical Sciences, Tabriz, Iran
Journal Article
2017
04
10
Colonic type villoglandular adenocarcinoma of the lower genital tract is an extremely rare condition. Its origin is not clearly understood; however, the cloacal remnants are the more accepted source for this carcinoma.We report the case of a 67-year-old female patient who presented with a 1.2 cm polypoidal nodule at the right side of the fourchette. Morphologic studies revealed a colonic type mucinous adenocarcinoma that arose from within a villous adenoma. Immunohistochemical staining showed positive cytokeratin 7, cytokeratin 20, carcinoembryonic antigen, P53, and progesterone receptor, but negative for estrogen receptor and caudal type homeobox transcription factor 2. Extensive work-up failed to reveal other primary cancers in this patient. Ultimately, she underwent a radical vulvectomy. No recurrence was seen in eight months follow up of this patient after surgery. Careful, thorough histological evaluation and clinical clues enable correct diagnosis of the rare colonic type vulvar villoglandular adenocarcinoma. Due to rarity of this tumor, its management is questionable. Therefore, additional investigation is necessary for its management.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
9
1
2018
01
01
Calendar of Events
76
42098
EN
Journal Article
2017
12
30